Cloudbreak Therapeutics, LLC   Report issue

For profit Phase 2 Phase 3
Founded: Irvine CA United States (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2017
NCT03049852
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Cloudbreak Therapeutics, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

nintedanib (ofev) (2 trials)

Drugs in Phase 2 Trials (3)

atropine (1 trial)

cbt-004 (1 trial)

cyclodextrin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pterygium (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4